KFDA approves Ildong’s novel antibiotic agent

Ildong Pharmaceutical Co. said Wednesday that it has received approval from the Korea Food and Drug Administration to conduct phase 1 clinical trial of PDF (peptide deformylase) inhibitor, a novel class of antibiotics.

PDF is recognized to be an attractive antibacterial target, as this enzyme has been demonstrated to be essential for bacterial growth in vitro, is not believed to be involved ...